{"id":227080,"date":"2026-05-22T14:16:39","date_gmt":"2026-05-22T12:16:39","guid":{"rendered":"https:\/\/efecomunica.efe.com\/?p=227080"},"modified":"2026-05-22T14:20:55","modified_gmt":"2026-05-22T12:20:55","slug":"chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu","status":"publish","type":"post","link":"https:\/\/efecomunica.efe.com\/en\/chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu\/","title":{"rendered":"CHMP issues positive opinion for JASCAYD\u00ae (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU"},"content":{"rendered":"<p><h1>CHMP issues positive opinion for JASCAYD\u00ae (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU<\/p>\n<\/h1>\n<div>\n<p><strong>Not intended for US and UK media<\/strong><\/p>\n<ul>\n<li>Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are life-threatening, progressive lung conditions that require early and sustained intervention<sup>1,2<\/sup><\/li>\n<li>CHMP\u2019s positive opinion is based on results from the Phase III FIBRONEER\u2122\ufe0f program, assessing the efficacy and safety of nerandomilast in IPF and PPF<sup>3,4<\/sup><\/li>\n<li>JASCAYD\u00ae (nerandomilast) is the first and only oral, preferential PDE4B inhibitor authorized for use in IPF and PPF in the US, China, the UAE, and Japan, and the first new IPF treatment in more than a decade<\/li>\n<\/ul>\n<p><strong>Ingelheim, Germany &#8211;<\/strong> Boehringer Ingelheim\u2019s JASCAYD<sup>\u00ae<\/sup>\u00a0(nerandomilast) has been recommended for marketing authorization by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF). This marks an important step toward making the first preferential PDE4B inhibitor available to patients living with these progressive and life-threatening lung conditions across the European Union.<\/p>\n<p>\u201cThe CHMP\u2019s positive opinion for JASCAYD\u00ae reflects the growing recognition that meaningful efficacy alongside a well\u2011tolerated profile is essential for enabling sustained treatment in IPF and PPF. This is vital to slow down the irreversible and life-threatening damage to the lungs and to address the high unmet need for patients whose prognosis is worse than that of many common cancers,\u201d said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. \u201cIf approved in the EU, JASCAYD\u00ae would mark the first new treatment option for IPF in Europe in more than a decade.\u201d<\/p>\n<p>The positive CHMP opinion is supported by results from FIBRONEER\u2122, the largest clinical trial program in IPF and PPF to date.<sup>3,4<\/sup>\u00a0Both Phase III trials, FIBRONEER\u2122-IPF and FIBRONEER\u2122-ILD, met their primary endpoint, demonstrating that nerandomilast slowed lung function decline measured by absolute change in forced vital capacity (FVC)* from baseline to week 52 compared to placebo.<sup>3,4<\/sup>\u00a0While the key secondary endpoint was not met in either trial,** there was a numerical reduction in mortality across both, reaching nominal significance in FIBRONEER\u2122-ILD.<sup>5<\/sup>\u00a0Nerandomilast demonstrated favorable safety and tolerability, with no requirement for liver monitoring. As monotherapy, it showed similar discontinuation rates to placebo.<sup>3,4\u00a0<\/sup><\/p>\n<p>\u201cCurrent treatments for IPF and PPF, including in patients whose PPF is associated with underlying autoimmune rheumatic diseases, have well\u2011known limitations. This is why advancing therapies with new mechanisms of action and better tolerability profiles is essential to improving how we manage these complex diseases,\u201d said Professor Anna\u2011Maria Hoffmann\u2011Vold, Professor of Rheumatology at the University of Zurich and Oslo University Hospital and investigator in the FIBRONEER\u2122 program. \u201cIn the FIBRONEER\u2122 trials, nerandomilast was well\u2011tolerated and slowed lung function decline, supporting its potential for long\u2011term use. This is imperative in conditions like IPF and PPF, including patients with an associated autoimmune rheumatic disease, which can worsen suddenly and unpredictably. Maintaining lung function for longer can therefore make a meaningful difference in clinical practice.\u201d<\/p>\n<p>Together, IPF and PPF affect more than 500,000 people across the EU.<sup>6<\/sup>\u00a0Both conditions are characterized by irreversible scarring of lung tissue that worsens over time, limiting people\u2019s ability to breathe. Approximately half of those diagnosed with IPF or PPF lose their lives within five years<sup>7,8,9<\/sup>\u00a0\u2013 a prognosis worse than that of many cancers.<sup>8,10,11<\/sup>\u00a0Despite the high mortality rate, many people delay starting existing therapies due to side effects such as nausea, photosensitivity, and diarrhea.<sup>12,13<\/sup>\u00a0In IPF specifically, approximately half of those who stop do so within six months.<sup>14<\/sup><\/p>\n<p>\u201cThe emotional toll of living with pulmonary fibrosis is overwhelming. This disease takes away independence, and the impact of losing the ability to do simple everyday tasks, such as showering, walking to the car, or catching your breath, is profound,\u201d said John K. Solheim, President of the European Pulmonary Fibrosis Federation (EU\u2011PFF). \u201cWhen patients are faced with treatment options that add unbearable side effects to the already burdensome symptoms, many choose to delay or stop taking them. A treatment option for IPF and PPF that works and has fewer side\u2011effects offers real hope to families across Europe.\u201d<\/p>\n<p><b>About IPF and PPF<\/b><\/p>\n<p>Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are both conditions\u00a0with\u00a0irreversible build-up of scar tissue in the lungs,\u00a0affecting the lungs\u2019 ability to take in and transfer oxygen into the bloodstream.<sup>15,16,17<\/sup>\u00a0Once\u00a0lung\u00a0function is lost,\u00a0it\u2019s\u00a0lost\u00a0forever.\u00a0Signs and symptoms of IPF and PPF include a persistent dry cough, shortness of breath, fatigue and finger\/toe clubbing (widening and rounding of the tips of fingers\/toes).<sup>2,17<\/sup><\/p>\n<p>In IPF, the root cause of pulmonary fibrosis is not known.<sup>14<\/sup>\u00a0The disease primarily affects people over the age of 50 and affects more men than women.<sup>18<\/sup><\/p>\n<p>In PPF, the scarring of the lungs may be linked to an existing condition (e.g.\u00a0rheumatoid arthritis or systemic sclerosis),\u00a0result\u00a0from exposure to inhaled substances (e.g. asbestos or mold),\u00a0or be\u00a0due to an unknown cause (idiopathic) and worsens despite treatment of the condition.<sup>16\u00a0<\/sup><\/p>\n<p>Together, IPF and PPF may affect up to 9.2\u00a0million people worldwide.<sup>6,19<\/sup>\u00a0Approximately half of people with IPF or PPF die within 5 years of diagnosis<sup>7,8,9<\/sup>\u00a0\u2013 a higher mortality than many cancers.<sup>8,10,11<\/sup><\/p>\n<p><b>About nerandomilast<\/b><\/p>\n<p>JASCAYD<sup>\u00ae<\/sup>\u00a0(nerandomilast) is a twice daily oral, preferential PDE4B inhibitor with antifibrotic and immunomodulatory effects approved in the U.S., China, the United Arab Emirates, and Japan for the treatment of adults with IPF and for the treatment of adults with PPF.<\/p>\n<p>Regulatory submissions for nerandomilast in IPF and PPF are also under review in the UK, and other countries with additional approvals anticipated in 2026.\u00a0<\/p>\n<p>Boehringer Ingelheim is also exploring the potential of nerandomilast in two rheumatic diseases: systemic sclerosis (SSc) and myositis (IIM).<\/p>\n<p><b>Boehringer Ingelheim<\/b><\/p>\n<p>Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry\u2019s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow.\u202fLearn more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=72HZpIt0p1EYU33VaxRcX9UHiHVVVL3j8X7piRBj5fkg873zb-J0SmfK0Z2kE9ld-DlWigNRATp25zxKb8DF0I_jRAa7hdixgphT4Pza7wAr9t6HfsP6NY0hvrYJAY2BC90Y8QhoK7WryQCEWawIV7regnKVcODrXq7b5NLRQtQU6stGXuxPr0o_1djD2RNR6Oqv-8XbABuX99KHFaXJui2ACg2paGVNUsQXpXaotIg=\" target=\"_blank\">www.boehringer-ingelheim.com<\/a>.\u00a0<\/p>\n<p><b>References<\/b><\/p>\n<p>*FVC is a measure of lung function, measured in mL.\u00a0<\/p>\n<p>**The key secondary endpoint was time to first acute IPF\/ILD exacerbation, first hospitalization for respiratory cause, or death over the duration of trial\u00a0<\/p>\n<ol>\n<li>Hoyer N, et al.\u00a0<em>Respir Res<\/em>. 2019;20(1).<\/li>\n<li>Grant-Orser A, et al.\u00a0<em>BMJ Open Respir Res.\u00a0<\/em>2024;11:e002333.<\/li>\n<li>Richeldi, et al.\u00a0<em>NEJM<\/em>. 2025;392:2193-2202.<\/li>\n<li>Maher T, et al.\u00a0<em>N Engl J Med<\/em>. 2025;392(22):2203-2214.<\/li>\n<li>Oldham JM, et\u202fal. ERS International Congress; 2025. Poster.<\/li>\n<li>Cottin V, et al.\u00a0<em>Front Med (Lausanne)<\/em>. 2022;9:799912.<\/li>\n<li>Zheng Q et al.\u00a0<em>ERJ Open Res<\/em>. 2022;8(1):00591-2021.<\/li>\n<li>Cen Z, et al<em>. Ann Med<\/em>. 2024;56(1):2406439.<\/li>\n<li>Nasser M, et al.\u00a0<em>Respir Res<\/em>\u00a02021;22:162.<\/li>\n<li>Siegel RL, et al.\u00a0<em>A Cancer Journal for Clinicians<\/em>.\u00a02024;74(1):12\u201349.<\/li>\n<li>Vancheri C, et al.\u00a0<em>Eur Respir J<\/em>. 2010;35(3):496\u2013504.<\/li>\n<li>Esbriet SmPC \u2014 Roche, 2014.<\/li>\n<li>Ofev SmPC \u2014 Boehringer\u202fIngelheim, 2025 (Last updated: Oct 2025).<\/li>\n<li>Levra S et al.\u00a0<em>Biomedicine<\/em>s. 2022;10(12):3229.<\/li>\n<li>Upagupta C, et al.\u00a0<em>Eur Respir Rev<\/em>. 2018;27:180033.<\/li>\n<li>Kondoh Y, Inoue Y.\u00a0<em>Adv Ther.<\/em>\u00a02025;42(7):2988\u20133001.<\/li>\n<li>van Cleemput, J, et al.\u00a0<em>Adv Ther<\/em>. 2019;36, 298\u2013317.<\/li>\n<li>Wang J, et al.\u00a0<em>MedComm<\/em>\u00a0(2020). 2024;5(10):e744.<\/li>\n<li>Podolanczuk A, et al.<em>\u00a0Eur Respir J<\/em>. 2023;614).<\/li>\n<\/ol>\n<p><\/p>\n<p><\/p>\n<p><img><br \/><img><\/div>\n<div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CHMP issues positive opinion for JASCAYD\u00ae (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU Not intended for US and UK media Idiopathic pulmonary fibrosis [&hellip;]<\/p>\n","protected":false},"author":198164071,"featured_media":48434,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[125518],"tags":[],"class_list":["post-227080","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CHMP issues positive opinion for JASCAYD\u00ae (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU - EFE Comunica<\/title>\n<meta name=\"description\" content=\"CHMP issues positive opinion for JASCAYD\u00ae (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU Not intended for US and UK\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/efecomunica.efe.com\/en\/chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu\/\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CHMP issues positive opinion for JASCAYD\u00ae (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU - EFE Comunica","description":"CHMP issues positive opinion for JASCAYD\u00ae (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU Not intended for US and UK","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/efecomunica.efe.com\/en\/chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/efecomunica.efe.com\/en\/chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu\/#article","isPartOf":{"@id":"https:\/\/efecomunica.efe.com\/en\/chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu\/"},"author":{"name":"EFE","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/person\/38c335f1ce4cd42430576ef5499343b8"},"headline":"CHMP issues positive opinion for JASCAYD\u00ae (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU","datePublished":"2026-05-22T12:16:39+00:00","dateModified":"2026-05-22T12:20:55+00:00","mainEntityOfPage":{"@id":"https:\/\/efecomunica.efe.com\/en\/chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu\/"},"wordCount":1238,"commentCount":0,"publisher":{"@id":"https:\/\/efecomunica.efe.com\/#organization"},"image":{"@id":"https:\/\/efecomunica.efe.com\/en\/chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu\/#primaryimage"},"thumbnailUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","articleSection":["Globenewswire"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/efecomunica.efe.com\/en\/chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/efecomunica.efe.com\/en\/chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu\/","url":"https:\/\/efecomunica.efe.com\/en\/chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu\/","name":"CHMP issues positive opinion for JASCAYD\u00ae (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU - EFE Comunica","isPartOf":{"@id":"https:\/\/efecomunica.efe.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/efecomunica.efe.com\/en\/chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu\/#primaryimage"},"image":{"@id":"https:\/\/efecomunica.efe.com\/en\/chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu\/#primaryimage"},"thumbnailUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","datePublished":"2026-05-22T12:16:39+00:00","dateModified":"2026-05-22T12:20:55+00:00","description":"CHMP issues positive opinion for JASCAYD\u00ae (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU Not intended for US and UK","breadcrumb":{"@id":"https:\/\/efecomunica.efe.com\/en\/chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/efecomunica.efe.com\/en\/chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/efecomunica.efe.com\/en\/chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu\/#primaryimage","url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","contentUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","width":1200,"height":650,"caption":"El \u00edndice Moneyball de Squawka clasifica a los clubes de la Premier League tomando en cuenta las \u00faltimas cinco temporadas (incluida la 2025\/26)."},{"@type":"BreadcrumbList","@id":"https:\/\/efecomunica.efe.com\/en\/chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/efecomunica.efe.com\/"},{"@type":"ListItem","position":2,"name":"CHMP issues positive opinion for JASCAYD\u00ae (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU"}]},{"@type":"WebSite","@id":"https:\/\/efecomunica.efe.com\/#website","url":"https:\/\/efecomunica.efe.com\/","name":"EFE Comunica","description":"Contenidos para empresas","publisher":{"@id":"https:\/\/efecomunica.efe.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/efecomunica.efe.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/efecomunica.efe.com\/#organization","name":"EFE Comunica","url":"https:\/\/efecomunica.efe.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/logo\/image\/","url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2020\/12\/Logo-EFE-Comunica_png.png","contentUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2020\/12\/Logo-EFE-Comunica_png.png","width":1080,"height":486,"caption":"EFE Comunica"},"image":{"@id":"https:\/\/efecomunica.efe.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/EFEComunicaAgenciaEFE","https:\/\/x.com\/EFEcomunica","https:\/\/www.linkedin.com\/showcase\/efecomunica"]},{"@type":"Person","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/person\/38c335f1ce4cd42430576ef5499343b8","name":"EFE","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","caption":"EFE"},"sameAs":["http:\/\/efe.com"],"url":"https:\/\/efecomunica.efe.com\/en\/author\/efedesarrollo\/"}]}},"jetpack_featured_media_url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","jetpack_likes_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pcEg1r-X4A","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/227080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/users\/198164071"}],"replies":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/comments?post=227080"}],"version-history":[{"count":1,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/227080\/revisions"}],"predecessor-version":[{"id":227081,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/227080\/revisions\/227081"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/media\/48434"}],"wp:attachment":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/media?parent=227080"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/categories?post=227080"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/tags?post=227080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}